Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florian Huemer

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Memo|December 19, 2017
ASCO-update: gastrointestinal tumorsLukas Weiss, Florian Huemer, Richard Greil
Memo|July 19, 2016
Immune checkpoint blockade in ovarian cancerLukas Weiss, Florian Huemer, Brigitte Mlineritsch, et al.
Pharmaceuticals (Basel, Switzerland)|February 3, 2021
miRNA-Based Therapeutics in the Era of Immune-Checkpoint InhibitorsFlorian Huemer, Michael Leisch, Roland Geisberger, et al.
Cancer Medicine|August 4, 2023
Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysisKonstantin Schlick, Antonia Gantschnigg, Alexander Seymer, et al.
Technology in Cancer Research & Treatment|October 1, 2021
Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospective Analysis of Twenty-Eight PatientsKonstantin Schlick, Dominik Kiem, Florian Huemer, et al.
Cancers|October 28, 2023
Unraveling Resistance to Immunotherapy in MSI-High Colorectal CancerRonald Heregger, Florian Huemer, Markus Steiner, et al.
International Journal of Molecular Sciences|April 25, 2020
Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial IntelligenceFlorian Huemer, Michael Leisch, Roland Geisberger, et al.
Cancers|October 3, 2020
Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 TherapyFlorian Huemer, Gudrun Piringer, Verena Schlintl, et al.
Clinical Colorectal Cancer|May 8, 2019
Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal CancerFlorian Huemer, Verena Schlintl, Stefan Hecht, et al.
BMC Cancer|January 5, 2018
Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)Florian Huemer, Josef Thaler, Gudrun Piringer, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Memo|December 19, 2017
ASCO-update: gastrointestinal tumorsLukas Weiss, Florian Huemer, Richard Greil
Memo|July 19, 2016
Immune checkpoint blockade in ovarian cancerLukas Weiss, Florian Huemer, Brigitte Mlineritsch, et al.
Pharmaceuticals (Basel, Switzerland)|February 3, 2021
miRNA-Based Therapeutics in the Era of Immune-Checkpoint InhibitorsFlorian Huemer, Michael Leisch, Roland Geisberger, et al.
Cancer Medicine|August 4, 2023
Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysisKonstantin Schlick, Antonia Gantschnigg, Alexander Seymer, et al.
Technology in Cancer Research & Treatment|October 1, 2021
Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospective Analysis of Twenty-Eight PatientsKonstantin Schlick, Dominik Kiem, Florian Huemer, et al.
Cancers|October 28, 2023
Unraveling Resistance to Immunotherapy in MSI-High Colorectal CancerRonald Heregger, Florian Huemer, Markus Steiner, et al.
International Journal of Molecular Sciences|April 25, 2020
Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial IntelligenceFlorian Huemer, Michael Leisch, Roland Geisberger, et al.
Cancers|October 3, 2020
Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 TherapyFlorian Huemer, Gudrun Piringer, Verena Schlintl, et al.
Clinical Colorectal Cancer|May 8, 2019
Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal CancerFlorian Huemer, Verena Schlintl, Stefan Hecht, et al.
BMC Cancer|January 5, 2018
Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)Florian Huemer, Josef Thaler, Gudrun Piringer, et al.
Pageof 5